Characteristics of individuals at-risk from a sub-cohort with at least 14 months of follow-up
| Developed RA (N=24) | Did not develop RA (N=21) | |
| Age, years: mean (SD) | 46 (12.6) | 45.8 (13.1) |
| Female, N (%) | 16 (66.7) | 13 (61.9) |
| Arthralgia, N (%) | 23 (95.8) | 20 (95.2) |
| Arthralgia duration, months: median (IQR) | 8.5 (5.3–32.5) | 24 (10–61) |
| time to RA diagnosis, months: median (IQR) | 4.5 (3–9.8) | – |
| IgA1 ACPA, µg/mL: median (IQR) | 4.6 (2.3–21.1) | 2.0 (1.4–7.3)* |
| IgA2 ACPA, µg/mL: median (IQR) | 0.82 (0.4–2.2) | 0.77 (0.3–2.2) |
| IgG ACPA, RU/mL: median (IQR) | 177.6 (49.4–394.9) | 38.5 (1.0–202.2)* |
*Higher IgA1 and IgG ACPA levels in RA at-risk individuals who developed RA, Mann-Whitney U test.
RA, rheumatoid arthritis; RU, relative units; t, test for age, exact Fisher’s test for sex and arthralgia and Mann-Whitney test for symptoms duration.